目的：探究利巴韦林注射液不良反应的特点，为临床合理用药提供参考。方法：以患者性别、 年龄、不良反应发生时间、过敏史、不良反应临床表现及转归等指标作为考查项，采用回顾性研究， 对2010年5月-2022年9月河南省药品不良反应监测中心收集的893例利巴韦林注射液不良反应报告进行分析。结果：893例不良反应患者中，男女比例为1.31 ：1，发生时间主要集中在用药30 min以内 (53.64%)。临床表现主要为全身性损害(26.78%)、皮肤及其附件损害(24.23%)、消化系统损害 (23.76%)、神经系统损害(11.30%)等。结论：上述结果提示利巴韦林注射液可引起不同程度的不良反应，临床用药时应给予足够重视，确保合理用药，密切关注患者用药变化，加强不良反应监测，提高用药安全性。
Abstract
Objective: To explore the characteristics of adverse drug reactions/events (ADR) of Ribavirin Injections and provide references for rational clinical medication. Methods: With patient’s gender, age, occurrence time of ADR, allergic history, clinical manifestations of ADR and outcome as the examination items, a retrospective study was performed to analyze 893 cases of ADR induced by Ribavirin Injection collected from Henan ADR Monitoring Center from May 2010 to September 2022. Results: The results indicated that among the 893 cases of ADR, the ratio of male to female was 1.31:1, the occurrence time of ADR cases mainly happened within 30 min (53.64%) of medication. The clinical manifestations were mainly affected systems included systemic lesion (26.78% ), skin and appendages (24.23%), digestive system(23.76%), central and peripheral nervous systems (11.30%), etc. Conclusion: These results suggested that a variety of degrees of ADR can be induced by Ribavirin Injection, while enough attention should be paid to the clinical use of Ribavirin Injection. To ensure rational use of the drugs, more close attention must be paid to the changes in patient’s medication, ADR monitoring also should be strengthened to improve the safety of medication.
关键词
利巴韦林注射液；不良反应；合理用药；分析；监测
{{custom_keyword}} /
Key words
Ribavirin Injection； adverse reactions； rational use of drug； analysis； monitoring of prescription
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 郭婷婷,陈灵,熊婉娟.新型冠状病毒肺炎患者使用利巴韦林注射液的用药分析、不良反应及药学监护[J].药物评价研究,2020,43(10):2085-2089.
[2] 郭洁茹,张锦文,赵丽.1071例利巴韦林不良反应/事件分析[J].药物流行病学杂志,2019,28(4):245-249.
[3] 国家药品不良反应监测中心,国家食品药品监督管理局药品评价中心.WHO药品不良反应术语集[M].北京:中国医药科技出版社,2003:103-172.
[4] 陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民出版社,2011:34-997
[5] 李清芳,刘欢,张丹丹,等.利巴韦林儿童应用风险分析与建议[J].中国药物警戒,2018,15(2):83-89.
[6] 刘维,于之恒,谈志远.从药代动力学角度看利巴韦林的静脉输注[J].临床药物治疗杂志,2020,18(2):67-70.
[7] 黄铁荣.利巴韦林在临床静脉滴注中的合理使用[J].北方药学,2015,12(1):121.
[8] 张春波,张勇.疑似头孢曲松利巴韦林联合双黄连注射液致死亡1例[J].医药导报,2017,36(7):833-834.
[9] 李冉,李艳艳.头孢曲松钠、利巴韦林联合用药致溶血性贫血并假性胆结石1例[J].儿科药学杂志,2015,21(10):65-66.
[10] 高健,乔炜超,夏青.大剂量利巴韦林注射液致新型冠状病毒肺炎患者急性溶血反应2例[J].药物不良反应杂志,2020,22(9):547-549.
[11] 高荣梅,李兴琼,何维英.利巴韦林注射液体内外抗流感病毒作用研究[J].药学学报,2010,45(3):403-407.
[12] Nisha Mistry,Jonathan Shapero,Richard I Crawford.AReview of Adverse Cutaneous Drug Reactions Resultingfrom the Use of Interferon and Ribavirin[J].CanadianJournal of Gastroenterology,2009,23(10):677-683.
[13] Patrick J Gavin,Ben Z Katz.Intravenous RibavirinT r e a t m e n t f o r S e v e r e A d e n o v i r u s D i s e a s e i nImmunocompromised Children[J].Pediatrics,2002,doi:10.1542/peds.110.1.e9.
[14] Yu-Chia Hsieh,Tsung-Zu Wu,Ding-Ping Liu,etal.Influenza Pandemics:Past,Present and Future[J].Journal of the Formosan Medical Association,2006,doi:10.1016/S0929-6646(09)60102-9.
[15] David Safronetz,Elaine Haddock,Friederike Feldmann,et al.In Vitro and in Vivo Activity of Ribavirin againstAndes Virus Infection[J].PloS One,2011,doi:10.1371/Journal.pone.0023560.
[16] E Sparrelid,P Ljungman,E Ekel?f-Andstr?m,et al.Ribavirin Therapy in Bone Marrow Transplant Recipientswith Viral Respiratory Tract Infections[J].Bone MarrowTransplantation,1997,doi:10.1038/sj.bmt.1700752.
[17] 靖百谦,周文,王凤山.利巴韦林临床应用进展[J].齐鲁药事,2006(7):417-418.
[18] 贺丽丽.急性上呼吸道感染经利巴韦林治疗的临床价值[J].深圳中西医结合杂志,2020,30(11):95-96.
[19] 彭碧苗,王启跃,徐秀余.利巴韦林注射液不良反应分析[J].临床合理用药杂志,2010,3(15):103-104.
[20] 胡巧织,罗敏,王华玲.基于FAERS的新型冠状病毒肺炎治疗用药安全信号挖掘研究:利巴韦林[J].医药导报,2020,39(4):513-518.
[21] 刘颖,魏春燕,沈超.利巴韦林用于病毒感染性疾病国内外文献分析[J].中国药业,2020,29(9):1-6.
[22] 黄辉明.急性上呼吸道感染患者热毒宁与利巴韦林联合治疗的临床研究[J].基层医学论坛,2017,21(29):4042-4043.
[23] 刘鹏,王国松.祖卡木颗粒联合利巴韦林治疗小儿急性上呼吸道感染的临床研究[J].现代药物与临床,2018,33(12):3204-3207.
[24] Mamta K Jain,Cindy Zoellner.Role of Ribavirin in HCVTreatment Response:Now and in the Future[J].ExpertOpinion on Pharmacotherapy,2010,11(4):673-683.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
